CA3242384A1 - Carbonic anhydrase ix ligands - Google Patents
Carbonic anhydrase ix ligandsInfo
- Publication number
- CA3242384A1 CA3242384A1 CA3242384A CA3242384A CA3242384A1 CA 3242384 A1 CA3242384 A1 CA 3242384A1 CA 3242384 A CA3242384 A CA 3242384A CA 3242384 A CA3242384 A CA 3242384A CA 3242384 A1 CA3242384 A1 CA 3242384A1
- Authority
- CA
- Canada
- Prior art keywords
- caix
- peptide
- compound
- compositions
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021086592 | 2021-12-17 | ||
| EPPCT/EP2021/086592 | 2021-12-17 | ||
| EPPCT/EP2022/054857 | 2022-02-25 | ||
| EP2022054857 | 2022-02-25 | ||
| EPPCT/EP2022/057170 | 2022-03-18 | ||
| EP2022057170 | 2022-03-18 | ||
| EP2022057840 | 2022-03-24 | ||
| EPPCT/EP2022/057840 | 2022-03-24 | ||
| EP2022067424 | 2022-06-24 | ||
| EPPCT/EP2022/067424 | 2022-06-24 | ||
| EPPCT/EP2022/079606 | 2022-10-24 | ||
| EP2022079606 | 2022-10-24 | ||
| EP2022081674 | 2022-11-11 | ||
| EPPCT/EP2022/081674 | 2022-11-11 | ||
| PCT/EP2022/086632 WO2023111350A2 (en) | 2021-12-17 | 2022-12-19 | Carbonic anhydrase ix ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242384A1 true CA3242384A1 (en) | 2023-06-22 |
Family
ID=84981172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242384A Pending CA3242384A1 (en) | 2021-12-17 | 2022-12-19 | Carbonic anhydrase ix ligands |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250339569A1 (https=) |
| EP (1) | EP4448544A2 (https=) |
| JP (1) | JP2025503451A (https=) |
| KR (1) | KR20240133798A (https=) |
| AR (1) | AR128023A1 (https=) |
| AU (1) | AU2022410422B2 (https=) |
| CA (1) | CA3242384A1 (https=) |
| CL (1) | CL2024001830A1 (https=) |
| IL (1) | IL313536A (https=) |
| MA (1) | MA66591A1 (https=) |
| MX (1) | MX2024007454A (https=) |
| TW (1) | TW202340226A (https=) |
| WO (1) | WO2023111350A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243979A1 (en) * | 2022-02-11 | 2025-04-30 | C-Biomex Co., Ltd. | Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses |
| AR133015A1 (es) * | 2023-06-20 | 2025-08-20 | Debiopharm Int Sa | Compuesto radiomarcado para su uso en un método de tratamiento de enfermedades con anhidrasa carbónica ix positiva |
| WO2025023747A1 (ko) * | 2023-07-25 | 2025-01-30 | (주)씨바이오멕스 | 탄산탈수소효소 ⅸ를 표적으로 하는 펩타이드 구조체 및 이들의 용도 |
| CN120943901A (zh) * | 2025-05-29 | 2025-11-14 | 北京肿瘤医院(北京大学肿瘤医院) | 经修饰的caix靶向环肽、核素标记物及其在肿瘤诊疗方面的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| WO2012016713A1 (en) | 2010-08-05 | 2012-02-09 | Ruprecht-Karls-Universität Heidelberg | Tumour targeting with polypeptides |
| WO2013172954A1 (en) * | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc | Peptide and peptidomimetic inhibitors |
| US10954287B2 (en) * | 2016-04-15 | 2021-03-23 | Ra Pharmaceuticals, Inc. | Ras binding peptides and methods of use |
| TW201919682A (zh) * | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Ｎｒｆ２路徑的新穎化合物 |
| WO2019096867A1 (en) | 2017-11-14 | 2019-05-23 | Debiopharm Research & Manufacturing S.A. | Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of cathepsin b |
| WO2020084305A1 (en) * | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| GB201900526D0 (en) | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for caix |
| GB201900525D0 (en) * | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for caix |
| JP7801207B2 (ja) * | 2019-07-08 | 2026-01-16 | ３ベー ファーマシューティカルズ ゲーエムベーハー | 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用 |
| TWI765195B (zh) | 2019-11-22 | 2022-05-21 | 行政院原子能委員會核能研究所 | 雙靶向碳酸酐酶第九型複合物及其造影劑 |
-
2022
- 2022-12-19 TW TW111148813A patent/TW202340226A/zh unknown
- 2022-12-19 CA CA3242384A patent/CA3242384A1/en active Pending
- 2022-12-19 AR ARP220103498A patent/AR128023A1/es unknown
- 2022-12-19 IL IL313536A patent/IL313536A/en unknown
- 2022-12-19 WO PCT/EP2022/086632 patent/WO2023111350A2/en not_active Ceased
- 2022-12-19 JP JP2024536171A patent/JP2025503451A/ja active Pending
- 2022-12-19 MA MA66591A patent/MA66591A1/fr unknown
- 2022-12-19 MX MX2024007454A patent/MX2024007454A/es unknown
- 2022-12-19 AU AU2022410422A patent/AU2022410422B2/en active Active
- 2022-12-19 US US18/720,400 patent/US20250339569A1/en active Pending
- 2022-12-19 KR KR1020247023840A patent/KR20240133798A/ko active Pending
- 2022-12-19 EP EP22843649.9A patent/EP4448544A2/en active Pending
-
2024
- 2024-06-17 CL CL2024001830A patent/CL2024001830A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023111350A2 (en) | 2023-06-22 |
| AR128023A1 (es) | 2024-03-20 |
| MX2024007454A (es) | 2024-09-02 |
| WO2023111350A3 (en) | 2023-07-27 |
| KR20240133798A (ko) | 2024-09-04 |
| AU2022410422B2 (en) | 2026-01-08 |
| US20250339569A1 (en) | 2025-11-06 |
| EP4448544A2 (en) | 2024-10-23 |
| MA66591A1 (fr) | 2025-05-30 |
| IL313536A (en) | 2024-08-01 |
| TW202340226A (zh) | 2023-10-16 |
| JP2025503451A (ja) | 2025-02-04 |
| AU2022410422A1 (en) | 2024-07-04 |
| CL2024001830A1 (es) | 2024-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3242384A1 (en) | Carbonic anhydrase ix ligands | |
| EA200700501A1 (ru) | Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества | |
| WO2005116051A3 (de) | An mhc-moleküle bindende tumor-assoziierte peptide | |
| MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
| WO2005023866A3 (en) | Peptides that inhibit complement activation | |
| WO2004110375A3 (en) | Combination therapy for the treatment of diabetes | |
| EP1626055A3 (en) | Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system | |
| CA2548915A1 (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
| GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
| WO2006034373A8 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
| MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
| PH12012501687A1 (en) | Acetylcysteine composition and uses therefor | |
| EP2384740A3 (en) | Oral care product and methods of use and manufacture thereof | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| WO2007102686A8 (en) | Peptides having activities of insulin like growth factor-1 and their uses | |
| WO2007112000A3 (en) | Treatment of pain | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| EA200500300A1 (ru) | Цитотоксические агенты, содержащие новые сильнодействующие таксаны, и их терапевтическое применение | |
| JP2011520846A5 (https=) | ||
| WO2007044396A3 (en) | Fibronectin polypeptides and methods of use | |
| WO2009019708A3 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| TW200639159A (en) | Treatment of pain | |
| EP2392322A3 (en) | Dosing regimes for trans-clomiphene | |
| EP1905426A3 (en) | Anti-acid pharmaceutical composition in powder form; pharmaceutical preparation containing it and process for making it | |
| KR20130049640A (ko) | 구강유용물질을 포함하는 구강용 캡슐 및 그 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240730 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241213 |